Ignite Creation Date:
2025-12-24 @ 2:49 PM
Ignite Modification Date:
2026-02-03 @ 1:30 PM
Study NCT ID:
NCT05064059
Status:
COMPLETED
Last Update Posted:
2025-09-17
First Post:
2021-09-29
Is Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
A Study of Coformulated Favezelimab/Pembrolizumab (MK-4280A) Versus Standard of Care in Subjects With Previously Treated Metastatic PD-L1 Positive Colorectal Cancer (MK-4280A-007)
Sponsor:
Merck Sharp & Dohme LLC
Organization:
Conditions & Keywords Data
Conditions:
Conditions
| Condition Brief | Condition Text | View |
|---|---|---|
| None | Colorectal Cancer | View |